RGRobert E. Gerszten

Robert E. Gerszten

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robert E. Gerszten has a total of 169 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Prospects for Cardiovascular Proteomics

    by Mark D. Benson, Marc S. Sabatine, Robert E. Gerszten


  • Metabolic Profiling of Right Ventricular-Pulmonary Vascular Function Reveals Circulating Biomarkers of Pulmonary Hypertension

    by Gregory D. Lewis, Debby Ngo, Anna R. Hemnes, Laurie Farrell, Carly Domos, Paul P. Pappagianopoulos, Bishnu P. Dhakal, Amanda Souza, Xu Shi, Meredith E. Pugh, et al.


  • Open Access

    Cross-sectional examination of metabolites and metabolic phenotypes in uremia

    by Sahir Kalim, Clary B. Clish, Joseph J. Deferio, Guillermo Ortiz, Alexander S. Moffet, Robert E. Gerszten, Ravi Thadhani, Eugene P. Rhee

    Although metabolomic approaches have begun to document numerous changes that arise in end stage renal disease (ESRD), how these alterations relate to established metabolic phenotypes in uremia is unknown. In 200 incident hemodialysis patients we used partial least squares discriminant analysis to identify which among 166 metabolites could best discriminate individuals with or without diabetes, and across tertiles of body mass index, serum albumin, total cholesterol, and systolic blood pressure. Our data do not recapitulate metabolomic signatures of diabetes and obesity identified among individuals with normal renal function (e.g. elevations in branched chain and aromatic amino acids) and highlight several potential markers of diabetes status specific to ESRD, including xanthosine-5-phosphate and vanillylmandelic acid. Further, our data identify significant associations between elevated tryptophan and long-chain acylcarnitine levels and both decreased total cholesterol and systolic blood pressure in ESRD. Higher tryptophan levels were also associated with higher serum albumin levels, but this may reflect tryptophan’s significant albumin binding. Finally, an examination of the uremic retention solutes captured by our platform in relation to 24 clinical phenotypes provides a framework for investigating mechanisms of uremic toxicity. In sum, these studies leveraging metabolomic and metabolic phenotype data acquired in a well-characterized ESRD cohort demonstrate striking differences from metabolomics studies in the general population, and may provide clues to novel functional pathways in the ESRD population.


  • Open Access

    Distinct metabolomic signatures are associated with longevity in humans

    by Susan Cheng, Martin G. Larson, Elizabeth L. McCabe, Joanne M. Murabito, Eugene P. Rhee, Jennifer E. Ho, Paul F. Jacques, Anahita Ghorbani, Martin Magnusson, Amanda L. Souza, et al.

    Alterations in metabolism influence lifespan in experimental models, but data in humans are lacking. Here we use liquid chromatography/mass spectrometry to quantify 217 plasma metabolites and examine their relation to longevity in a large cohort of men and women followed for up to 20 years. We find that, higher concentrations of the citric acid cycle intermediate, isocitrate, and the bile acid, taurocholate, are associated with lower odds of longevity, defined as attaining 80 years of age. Higher concentrations of isocitrate, but not taurocholate, are also associated with worse cardiovascular health at baseline, as well as risk of future cardiovascular disease and death. None of the metabolites identified are associated with cancer risk. Our findings suggest that some, but not all, metabolic pathways related to human longevity are linked to the risk of common causes of death.


  • Top Cited Papers

    β-Aminoisobutyric Acid Induces Browning of White Fat and Hepatic β-Oxidation and Is Inversely Correlated with Cardiometabolic Risk Factors

    by Lee D. Roberts, Pontus Boström, John F. O’sullivan, Robert T. Schinzel, Gregory D. Lewis, Andre Dejam, Youn-Kyoung Lee, Melinda J. Palma, Sondra Calhoun, Anastasia Georgiadi, et al.


  • Top Cited Papers
    Open Access

    2-Aminoadipic acid is a biomarker for diabetes risk

    by Thomas J. Wang, Debby Ngo, Nikolaos Psychogios, Andre Dejam, Martin G. Larson, Ramachandran S. Vasan, Anahita Ghorbani, John O’sUllivan, Susan Cheng, Eugene P. Rhee, et al.

    Improvements in metabolite-profiling techniques are providing increased breadth of coverage of the human metabolome and may highlight biomarkers and pathways in common diseases such as diabetes. Using a metabolomics platform that analyzes intermediary organic acids, purines, pyrimidines, and other compounds, we performed a nested case-control study of 188 individuals who developed diabetes and 188 propensity-matched controls from 2,422 normoglycemic participants followed for 12 years in the Framingham Heart Study. The metabolite 2-aminoadipic acid (2-AAA) was most strongly associated with the risk of developing diabetes. Individuals with 2-AAA concentrations in the top quartile had greater than a 4-fold risk of developing diabetes. Levels of 2-AAA were not well correlated with other metabolite biomarkers of diabetes, such as branched chain amino acids and aromatic amino acids, suggesting they report on a distinct pathophysiological pathway. In experimental studies, administration of 2-AAA lowered fasting plasma glucose levels in mice fed both standard chow and high-fat diets. Further, 2-AAA treatment enhanced insulin secretion from a pancreatic β cell line as well as murine and human islets. These data highlight a metabolite not previously associated with diabetes risk that is increased up to 12 years before the onset of overt disease. Our findings suggest that 2-AAA is a marker of diabetes risk and a potential modulator of glucose homeostasis in humans.


  • Top Cited Papers
    Open Access

    A Combined Epidemiologic and Metabolomic Approach Improves CKD Prediction

    by Eugene P. Rhee, Clary B. Clish, Anahita Ghorbani, Martin G. Larson, Sammy Elmariah, Elizabeth McCabe, Qiong Yang, Susan Cheng, Kerry Pierce, Amy Deik, et al.

    Metabolomic approaches have begun to catalog the metabolic disturbances that accompany CKD, but whether metabolite alterations can predict future CKD is unknown. We performed liquid chromatography/mass spectrometry–based metabolite profiling on plasma from 1434 participants in the Framingham Heart Study (FHS) who did not have CKD at baseline. During the following 8 years, 123 individuals developed CKD, defined by an estimated GFR of 2. Numerous metabolites were associated with incident CKD, including 16 that achieved the Bonferroni-adjusted significance threshold of P≤0.00023. To explore how the human kidney modulates these metabolites, we profiled arterial and renal venous plasma from nine individuals. Nine metabolites that predicted CKD in the FHS cohort decreased more than creatinine across the renal circulation, suggesting that they may reflect non–GFR-dependent functions, such as renal metabolism and secretion. Urine isotope dilution studies identified citrulline and choline as markers of renal metabolism and kynurenic acid as a marker of renal secretion. In turn, these analytes remained associated with incident CKD in the FHS cohort, even after adjustment for eGFR, age, sex, diabetes, hypertension, and proteinuria at baseline. Addition of a multimarker metabolite panel to clinical variables significantly increased the c-statistic (0.77–0.83, PP<0.0001). Thus, the addition of metabolite profiling to clinical data may significantly improve the ability to predict whether an individual will develop CKD by identifying predictors of renal risk that are independent of estimated GFR.


  • Top Cited Papers

    A Genome-wide Association Study of the Human Metabolome in a Community-Based Cohort

    by Eugene P. Rhee, Jennifer E. Ho, Ming-Huei Chen, Dongxiao Shen, Susan Cheng, Martin G. Larson, Anahita Ghorbani, Xu Shi, Iiro T. Helenius, Christopher J. O’dOnnell, et al.


  • Toward New Biomarkers of Cardiometabolic Diseases

    by Lee D. Roberts, Robert E. Gerszten


  • Top Cited Papers

    Metabolite Profiling Identifies Pathways Associated With Metabolic Risk in Humans

    by Susan Cheng, Eugene P. Rhee, Martin G. Larson, Gregory D. Lewis, Elizabeth L. McCabe, Dongxiao Shen, Melinda J. Palma, Lee D. Roberts, Andre Dejam, Amanda L. Souza, et al.

    Background—: Although metabolic risk factors are known to cluster in individuals who are prone to developing diabetes mellitus and cardiovascular disease, the underlying biological mechanisms remain poorly understood. Methods and Results—: To identify pathways associated with cardiometabolic risk, we used liquid chromatography/mass spectrometry to determine the plasma concentrations of 45 distinct metabolites and to examine their relation to cardiometabolic risk in the Framingham Heart Study (FHS; n=1015) and the Malmö Diet and Cancer Study (MDC; n=746). We then interrogated significant findings in experimental models of cardiovascular and metabolic disease. We observed that metabolic risk factors (obesity, insulin resistance, high blood pressure, and dyslipidemia) were associated with multiple metabolites, including branched-chain amino acids, other hydrophobic amino acids, tryptophan breakdown products, and nucleotide metabolites. We observed strong associations of insulin resistance traits with glutamine (standardized regression coefficients, −0.04 to −0.22 per 1-SD change in log-glutamine; P P P P =0.03) but not in MDC. In experimental models, administration of glutamine in mice led to both increased glucose tolerance ( P =0.01) and decreased blood pressure ( P <0.05). Conclusions—: Biochemical profiling identified circulating metabolites not previously associated with metabolic traits. Experimentally interrogating one of these pathways demonstrated that excess glutamine relative to glutamate, resulting from exogenous administration, is associated with reduced metabolic risk in mice.